|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Bivalirudin#Adult Indications and Dosage]] |
| {{Bivalirudin}}
| |
| {{CMG}} {{AE}}{{JH}}
| |
|
| |
|
| ==Indications and Usage==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===1.1 Percutaneous Transluminal Coronary Angioplasty (PTCA)===
| | [[Category: Anticoagulants]] |
| | |
| Angiomax® (bivalirudin) is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
| |
| | |
| ===1.2 Percutaneous Coronary Intervention (PCI)===
| |
| | |
| Angiomax with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as listed in the REPLACE-2 trial [see Clinical Studies (14.1)] is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
| |
| | |
| Angiomax is indicated for patients with, or at risk of, heparin induced thrombocytopenia (HIT) or heparin induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing PCI.
| |
| | |
| ===1.3 Use with Aspirin===
| |
| | |
| Angiomax in these indications is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin [see Dosage and Administration (2.1) and Clinical Studies (14.1)].
| |
| | |
| ===1.4 Limitation of Use===
| |
| | |
| The safety and effectiveness of Angiomax have not been established in patients with acute coronary syndromes who are not undergoing PTCA or PCI.<ref>{{Cite web | last = | first = | title = ANGIOMAX (BIVALIRUDIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [THE MEDICINES COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=911cd48f-01ea-4dec-b30c-95e7e0ea9d2a | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |